Peer-Reviewed Publication Validates RenovaCare Approach to Rapidly-Processing Stem Cells for Burns and Wounds

NEW YORK & PITTSBURGH–(BUSINESS WIRE)– RenovaCare,
Inc., (OTCQB:RCAR), has announced that its approach to
isolating a patient’s own stem cells for subsequent spray onto burns and
wounds has been validated by researchers in ‘Differentiation’, a leading
peer-reviewed scientific publication. According to their findings, the
methodology, which has been adopted by RenovaCare, successfully isolates
those specific cell populations with the greatest regenerative capacity
to support the growth of fully-functioning skin.

This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20170711005405/en/

RenovaCare Stem Cell Approach Validated by Peer-Reviewed Publication (Photo: Business Wire)

Today’s announcement follows recent highlights from an independent
analysis of treatment results on a variety of wide-area and severe burn
injuries published in Burns, the peer-reviewed Journal of the
International Society for Burn Injuries. The treatment method, adopted
by RenovaCare, involved isolating and spraying the patient’s own skin
stem cells on the burn wounds, and it is the technology underlying the
company’s patented CellMist™ and SkinGun™.

(Click
here to see before-after photos of severe second-degree burn patients
who received skin stem cell spray grafting treatment; Journal Burns.)

RenovaCare harvests a patient’s stem cells from a small area of skin, as
little as one-inch square. These cells are placed in a water-based
suspension and delicately sprayed onto the wound using the RenovaCare
SkinGun™, where the cells begin growing new skin.

As in the case of state trooper Matt
Uram, one of dozens of burn victims treated with autologous skin
stem cell spray, patients are able to leave the hospital within only a
few days rather than the many weeks required by alternative treatments
such as in-vitro cultured epithelial grafts.

In contrast to the speed and effectiveness of the RenovaCare procedure
— taking as little as 90-minutes — in-vitro cultured grafts require
harvesting cells from a patient, which are then transported to a
specialized external laboratory where they take weeks to form sheets of
skin. These fragile sheets must then be sent back to the hospital for
surgical stitching onto a patient’s wounds, a process that is
complicated, time-consuming and expensive.

“It’s very exciting to have this scientific validation that our approach
is ideal for rapid and natural skin regeneration,” explained Mr. Thomas
Bold, President and CEO of RenovaCare, Inc. “We’ve always had confidence
that our methodology isolates the body’s most regenerative cell
population before spray application with our ultra-gentle SkinGun™.”

In the 2015 article published in ‘Differentiation’, researchers
identified the advantages of freshly-isolated cells and compared their
regenerative properties against the concept of culturing skin cells,
used to grow sheets of skin.

Findings demonstrate that, under the tested conditions, freshly-isolated
skin cells have far greater regenerative capacity than cells which have
been repeatedly cultured. Cultured cells lose specific cell populations
which support skin regeneration, necessary to healing.

In the RenovaCare approach, adopted from the study, freshly isolated
cells derived from the basal layer grow both in size and number and
include rapid-cycling cells responsible for quick healing. The high
presence of these cells assures entirely natural regeneration of the
skin without the use of external chemical support, growth factors, and
drugs — important advantages highlighted by RenovaCare.

According to authors of the ‘Differentiation’ publication, the approach
of applying freshly isolated stem cells to the wound is, “A concept that
is thought to preserve the proliferative and regenerative capabilities
of basal layer derived cells for the patient’s wound healing in a more
physiological way than applying the cells to the same wound only after
several weeks of in vitro culture.”

The paper further concludes that by directly applying these
freshly-isolated cells onto the wound, the patient’s own body can
provide the nutrients and vascular support needed in order to promote
skin regeneration.

The article titled, “In vitro keratinocyte expansion for cell
transplantation therapy is associated with differentiation and loss of
basal layer derived progenitor population,” by: Roger Esteban-Vives,
Matthew T. Young, Patrick Over, Eva Schmeltzer, Alain Corcos, Jenny
Ziembicki, and Jörg Gerlach, was published in June 2015 by Elsevier in
Differentiation. (doi: 10.1016/j.diff.2015.05.002.)

Copies of the article are available to credentialed journalists upon
request; please contact Elsevier’s Newsroom at newsroom@elsevier.com or
+31 20 485 2492.

Study authors, Dr. Roger Esteban-Vives and Dr. Jörg Gerlach currently
have a financial interest in the SkinGun™ spray-grafting technology
through payments from RenovaCare, Inc. Dr. Esteban-Vives, currently
Director of Cell Sciences at RenovaCare, Inc., was a postdoctoral fellow
at the University of Pittsburgh when this work was conducted and did not
have such financial interest at that time.

*RenovaCare products are currently in development. They are not
available for sale in the United States. There is no
assurance that the company’s planned or filed submissions to the U.S.
Food and Drug Administration, if any, will be accepted or cleared by the
FDA.

About Burns

Burns aims to foster the exchange of information among all
engaged in preventing and treating the effects of burns. The journal
focuses on clinical, scientific, and social aspects of these injuries
and covers the prevention of the injury, the epidemiology of such
injuries, and all aspects of treatment including development of new
techniques and technologies and verification of existing ones. Regular
features include clinical and scientific papers, state of the art
reviews, and descriptions of burn-care in practice.

About RenovaCare, Inc.

RenovaCare, Inc. is developing first-of-its-kind autologous
(self-donated) stem cell therapies for the regeneration of human organs.
Its initial product under development targets the body’s largest organ,
the skin. The company’s flagship technology, the CellMist™ System, uses
its patented SkinGun™ to spray a liquid suspension of a patient’s stem
cells – the CellMist™ Solution – onto wounds. RenovaCare is developing
its CellMist™ System as a promising new alternative for patients
suffering from burns, chronic and acute wounds, and scars. In the US
alone, this $45 billion market is greater than the spending on
high-blood pressure management, cholesterol treatments, and back pain
therapeutics.

For additional information, please call Drew Danielson at: 888-398-0202
or visit:
http://renovacareinc.com

To receive future press releases via email, please visit:
https://renovacareinc.com/register/

Follow us on Twitter https://twitter.com/Renovacareinc
or follow us on Facebook https://www.facebook.com/renovacarercar

For answers to frequently asked questions, please visit our FAQ’s page:
https://renovacareinc.com/faqs/

Social Media Disclaimer

Investors and others should note that we announce material financial
information to our investors using SEC filings and press releases. We
use our website and social media to communicate with our subscribers,
shareholders, and the public about the company, RenovaCare, Inc.
development, and other corporate matters that are in the public domain.
At this time, the company will not post information on social media that
could be deemed to be material information unless that information was
distributed to public distribution channels first. We encourage
investors, the media, and others interested in the company to review the
information we post on the company’s website and the social media
channels listed below:

• Facebook

• Twitter

* This list may be updated from time to time.

Legal Notice Regarding Forward-Looking Statements

No statement herein should be considered an offer or a solicitation of
an offer for the purchase or sale of any securities. This release
contains forward-looking statements that are based upon current
expectations or beliefs, as well as a number of assumptions about future
events. Although RenovaCare, Inc. (the “Company”) believes that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, it can give no
assurance that such expectations and assumptions will prove to have been
correct. Forward-looking statements, which involve assumptions and
describe our future plans, strategies, and expectations, are generally
identifiable by use of the words “may,” “will,” “should,” “could,”
“expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or
the negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements are
subject to numerous factors and uncertainties, including but not limited
to: the timing and success of clinical and preclinical studies of
product candidates, the potential timing and success of the Company’s
product programs through their individual product development and
regulatory approval processes, adverse economic conditions, intense
competition, lack of meaningful research results, entry of new
competitors and products, inadequate capital, unexpected costs and
operating deficits, increases in general and administrative costs,
termination of contracts or agreements, obsolescence of the Company’s
technologies, technical problems with the Company’s research, price
increases for supplies and components, litigation and administrative
proceedings involving the Company, the possible acquisition of new
businesses or technologies that result in operating losses or that do
not perform as anticipated, unanticipated losses, the possible
fluctuation and volatility of the Company’s operating results, financial
condition and stock price, losses incurred in litigating and settling
cases, dilution in the Company’s ownership of its business, adverse
publicity and news coverage, inability to carry out research,
development and commercialization plans, loss or retirement of key
executives and research scientists, and other risks. There can be no
assurance that further research and development will validate and
support the results of our preliminary research and studies. Further,
there can be no assurance that the necessary regulatory approvals will
be obtained or that the Company will be able to develop commercially
viable products on the basis of its technologies. In addition, other
factors that could cause actual results to differ materially are
discussed in the Company’s most recent Form 10-Q and Form 10-K filings
with the Securities and Exchange Commission. These reports and filings
may be inspected and copied at the Public Reference Room maintained by
the U.S. Securities & Exchange Commission at 100 F Street, N.E.,
Washington, D.C. 20549. You can obtain information about operation of
the Public Reference Room by calling the U.S. Securities & Exchange
Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission
also maintains an Internet site that contains reports, proxy and
information statements, and other information regarding issuers that
file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov.
The Company undertakes no obligation to publicly release the results of
any revisions to these forward-looking statements that may be made to
reflect the events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170711005405/en/